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ABSTRACT
Age, sex and presence of comorbidities are risk factors associated with COVID-19. 
Hypertension, diabetes and heart disease are the most common comorbidities in patients 
with COVID-19. The objective of this study was to estimate the prevalence of patients with 
comorbidities who died of COVID-19 in Brazil. Searches of data were carried out on the 
official pages of the 26 State health departments and the federal district. The random-effect 
method was used to calculate the prevalence of patients with comorbidities who died. From 
the beginning of the pandemic in Brazil until May 20, 2020, 276,703 cases of COVID-19 were 
notified in Brazil, 6.4% died, 58.6% of whom were male. The prevalence of comorbidities 
among deaths was 83% (95% CI: 79 - 87), with heart disease and diabetes being the most 
prevalent. To our knowledge, this study represents the first large analysis of cases of patients 
with confirmed COVID-19 in Brazil. There is a high prevalence of comorbidities (83%) 
among patients who died from COVID-19 in Brazil, with heart disease being the most 
prevalent. This is important considering the possible secondary effects produced by drugs 
such as hydroxychloroquine.
KEYWORDS: COVID-19. Prevalence. Deaths. Comorbidities. Brazil. Heart disease. 
Diabetes. 
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic has infected more than 
seven million people worldwide in 216 countries, and, until Jun 16, 2020, it had 
caused over four hundred thousand deaths1. Its etiological agent is the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), transmitted by contact with an 
infected person or contaminated fluids2,3.
A multicenter cohort study showed that gender and advanced age are 
significantly correlated with COVID-19 and these findings are consistent with the 
higher incidence among older people and men4. Another study observed that the 
presence of any comorbidity increases the patient’s risk of developing respiratory 
distress, possibly leading to an intensive care unit (ICU) hospitalization and/or 
death5,6. Cardiovascular diseases, diabetes, hypertension, and chronic obstructive 
pulmonary disease are among the most prevalent comorbidities in COVID-19 
cases7. 
In Brazil, the first confirmed case of COVID-19 was reported on February 26, 
20208, and the first known death was reported 20 days later, on March 17. Until 
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June 21, the country had confirmed 1,073,376 cases and 
50,182 deaths, with an incidence of 5.08 cases per million 
inhabitants. 
This study aimed to estimate the prevalence of patients 
with comorbidities that died of COVID-19 in the Brazilian 
Federative Units.
METHODS
Data were extracted from the bulletin on the 
epidemiological situation of COVID-19, made available 
by each of the 26 Brazilian States and the Federal District, 
on their official websites. The obtained data were evaluated 
according to the following variables: confirmed cases, 
ICU hospitalizations and deaths. The epidemiological and 
clinical profiles of the death’s cases were also described, 
considering sex, age, and the presence and type of 
comorbidities, respectively.
Because not all States reported the presence of 
comorbidities in fatal cases, the random-effects model to 
estimate the pooled prevalence of comorbidities in deaths 
and their respective confidence intervals (CI) of 95%, was 
used. The heterogeneity of prevalence was analyzed by State 
using the Higgins test (I2), which presents the percentage 
of variation across them. These analyses were performed 
using the Stata statistical software, version 12 (Stata Corp 
LLC, Texas, USA). 
RESULTS 
Data collection from the official websites of each State 
Health Department took place from the beginning of the 
pandemic in Brazil to May 20, 2020. During this period, we 
found 276,703 reported cases of COVID-19, among which 
11,278 (4.8%) were admitted to ICU, and 17,752 (6.4%) 
cases resulted in deaths. 
When analyzing ICU hospitalization percentage by 
State, Rio de Janeiro (23.3%) and Minas Gerais (19.6%) 
were the States with the highest prevalences. (Table 1) 
The States with the highest death percentages were: 
Rio de Janeiro (10.7%), Para (9.4%), Sao Paulo (7.8%), 
Pernambuco (8.1%), Amazonas (6.9%) and Parana (5.2%). 
Table 1 shows the percentages for each State.
Regarding the epidemiological profile of fatal cases, 
22 States segregated a total of 7,531 cases by sex, of which 
58.6% were male and 41.4% female. The age of the death 
cases was reported only in epidemiological bulletins of 
25 States. From 17,752 cases of death, only in 14,728 
(83%) the age was reported, the population over 60 years 
old was the most affected (71.4%) (Table 1). Conversely, 
the clinical profile was only reported in 2,116 deaths (12%) 
from 15 States, 1,768 of which presented comorbidities, 
resulting in an 83% prevalence (95% CI: 79 – 87) (Table 1).
The clinical descriptions of the comorbidities in the 
death cases were extracted from the epidemiological 
bulletins of each State, which reported diseases grouped 
according to: Chronic Heart Diseases, Diabetes, Chronic 
Lung Diseases (including Chronic Obstructive Pulmonary 
Disease and asthma), Chronic Kidney Diseases, Stroke, 
Hypertension, Obesity, Immunosuppressive Diseases, 
Chronic Liver Diseases, Cancer, Digestive System Diseases, 
Pneumonia, Hematological diseases, Tuberculosis, 
Metabolic Diseases (different than diabetes), Smoking 
habit, Others (not specified).
Among the cases of death, that showed one or more 
previous diseases, a total of 14,737 comorbidities were 
recorded. The most prevalent comorbidities found were: 
35% chronic heart diseases, 28.7% diabetes, 8.2% 
chronic lung diseases (including asthma and Chronic 
Obstructive Pulmonary Disease), 5.9% kidney diseases, 
5.3% stroke, 5.1% hypertension, 4.4% obesity, and 3.8% 
immunosuppressive diseases (Table 2). 
DISCUSSION
To our knowledge, this study represents the first large 
analysis of cases of sequentially patients with confirmed 
COVID-19 in Brazil. By June 21, 2020, Brazil was the 
second country in number of confirmed cases of COVID-19, 
reporting over a million cases of confirmed COVID-19 and 
our analysis included approximately a quarter of these cases. 
As in different parts of the world, a higher prevalence in 
men and people aged 60 years or in elderly people were 
found among deaths by COVID-199-11.
We found that 4.8% of COVID-19 patients were 
admitted to ICU, a percentage comparable with a previous 
study conducted in the United States of America (USA) 
that analyzed 74,439 COVID-19 patients, among whom 
1.4% required ICU12. Data collected from 138 patients in 
China showed that 26% were admitted to ICUs13. Thus, 
States such as Rio de Janeiro and Minas Gerais, with the 
highest hospitalization percentages in the country (23.3% 
and 19.6%, respectively), should strengthen measures to 
avoid the collapse of their hospitals intensive care units. 
By June 21, 2020, Brazil has exceeded 50,000 
deaths, a mark, so far, reached by only two countries 
worldwide. Considering that, Rio de Janeiro, Para, Sao 
Paulo, Pernambuco, and Amazonas, which present higher 
percentages than that calculated for the overall country, 
represent a great national concern. When dealing with the 
COVID-19 pandemic, mortality, as well as establishing 
priorities for controlling it, is the most important concern. 
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The capacity of the healthcare system thus becomes a major 
issue, especially considering that the number of confirmed 
cases in communities is rapidly increasing, as is the case 
in Brazil.
The pooled prevalence of comorbidities in deaths 
by COVID-19 in Brazil was 83% (95% CI: 79 – 87). 
Previous studies conducted in Korea (90.7%) and China 
(68.2%) warned about a higher prevalence of severe 
acute respiratory syndrome caused by SARS-CoV-2 
among patients with comorbidities11,14. They also point 
hypertension, cardiovascular diseases, and diabetes as the 
main comorbidities among deaths by the disease. Several 
studies suggest that hypertension is the most common 
comorbidity in COVID-19 patients15. Likewise, a meta-
analysis carried out recently by our team showed that 
hypertension is the most prevalent comorbidity among 
deaths from COVID-19, followed by diabetes and chronic 
heart diseases ranking third16. Now, in Brazil we found 
that the main comorbidities among deaths are chronic 
heart diseases and diabetes. The third most common 
comorbidity were the chronic lung diseases, followed by 
chronic kidney diseases, stroke, hypertension, obesity 
and immunosuppressive diseases which may include HIV 
infection and organ transplant patients. 
Table 1 - Distribution of epidemiological and clinical variables from confirmed and deaths cases of COVID-19, according to the 
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AC 2,234 16 0.7 67 3.0 67 42 62.7 76 65 - 85
AL 4,031 N.S. N.S. 221 5.5 221 145 65.6 N.S. N.S.
AP 4,310 80 1.9 136 3.2 0 0 0.0 N.S. N.S.
AM 20,913 190 0.9 1,433 6.9 0 0 0.0 N.S. N.S.
BA 8,881 N.S. N.S. 312 3.5 312 210 67.3 86 82 - 89
CE 28,092 646 2.3 1,312 4.7 750 378 28.8 N.S. N.S.
DF 4,618 121 2.6 66 1.4 62 48 72.7 89 80 - 95
ES 4,412 N.S. N.S. 172 3.9 172 128 74.4 N.S. N.S.
GO 1,114 87 7.8 51 4.6 51 37 72.5 65 51 - 76
MA 15,114 N.S. N.S. 634 4.2 634 476 75.1 86 83 - 89
MT 1,695 48 2.8 32 1.9 32 18 56.3 91 76 - 97
MS 693 11 1.6 17 2.5 17 13 76.5 94 73 - 99
MG 5,286 1,038 19.6 177 3.3 177 133 75.1 90 84 - 93
PA 18,929 304 1.6 1,778 9.4 1,778 1,247 70.1 N.S. N.S.
PB 5,838 N.S. N.S. 230 3.9 230 145 63.0 N.S. N.S.
PR 2,616 78 3.0 137 5.2 137 94 68.6 66 57 - 73
PE 22,560 229 1.0 1,834 8.1 1,834 1,316 71.8 N.S. N.S.
PI 2,852 139 4.9 91 3.2 91 67 73.6 90 82 - 95
RJ 30,372 7,084 23.3 3,237 10.7 3,237 2,333 72.1 N.S. N.S.
RN 3,796 137 3.6 170 4.5 169 110 64.7 81 74 -86
RS 4,972 233 4.7 139 2.8 139 118 84.9 94 88 - 97
RO 2,499 N.S. N.S. 90 3.6 43 28 31.1 82 73 - 89
RR 3,296 N.S. N.S. 64 1.9 64 36 56.3 47 35 - 59
SC 5,499 107 1.9 94 1.7 94 67 71.3 N.S. N.S.
SP 65,995 521 0.8 5,147 7.8 4,343 3,315 64.4 N.S. N.S.
SE 4,277 178 4.2 69 1.6 74 47 68.1 93 84 - 97
TO 1,809 31 1.7 42 2.3 42 5 11.9 N.S. N.S.
Total 276,703 11,278 4.1 17,752 6.4 14,770 10,551 71.4 83 79 - 87
Source: The epidemiological and clinical profiles of confirmed and deaths cases of COVID-19 were obtained through the bulletin 
information on the epidemiological situation of COVID-19, which each Brazilian State makes available on its official websites. 
ICUs = Patients admitted to intensive care units; 95% CI = 95% confidence interval; N.S. = Not specified. AC (Acre); AL (Alagoas); 
AP (Amapa); AM (Amazonas); BA (Bahia); CE (Ceara); DF (Distrito Federal); ES (Espirito Santo); GO (Goias); MA (Maranhao); 
MT (Mato Grosso); MS (Mato Grosso do Sul); MG (Minas Gerais); PA (Para); PB (Paraiba); PR (Parana); PE (Pernambuco); 
PI (Piaui); RJ (Rio de Janeiro); RN (Rio Grande do Norte); RS (Rio Grande do Sul); RO (Rondonia); RR (Roraima); SC (Santa 
Catarina); SP (Sao Paulo). SE (Sergipe); TO (Tocantins). 
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The epidemiological bulletins of each State do not 
specify what were the chronic heart diseases of patients 
who died from COVID-19, although this group may 
include patients with coronary heart disease, arrhythmias, 
infarction, patients with pacemakers and others. Our 
results showed that this group of comorbidities was the 
most important in the population studied, and this is an 
important finding, because the Ministry of Health defends 
the use of hydroxychloroquine for treating COVID-19. 
A recent study claims that some cardiac manifestations, 
such as cardiac arrhythmias, and even conduction 
disorders without repercussion, may represent the initial 
manifestations of toxicity related to chloroquine or 
hydroxychloroquine17. Therefore, the use of these drugs 
can lead to serious complications and even death in 
patients with previous heart disease. On the other hand, 
the use of these drugs as post exposure prophylaxis (PEP), 
has also proved unsuccessful18.
Some difficulties to develop this study were found. 
Firstly, not every Health Department updates their 
epidemiological bulletins daily, so the updating of data on 
a daily basis was unfeasible. Secondly, the epidemiological 
bulletins were not standardized, not all of them provide 
epidemiological data such as age, nor clinical data such as 
the presence of comorbidities, which impaired the collection 
of complete data. Thirdly, many epidemiological bulletins 
provide information only as graphics and the absolute 
numbers were lacking, hampering data replication. Finally, 
each Secretariat reported different age groups, which 
impaired the comparisons among them. 
We concluded that there is a high prevalence of 
comorbidities among deaths by COVID-19, affecting 
mainly men aged over 60 years. The group of chronic 
heart diseases and diabetes were the main comorbidities 
among these patients and this is relevant considering 
the possible adverse effects produced by drugs such as 
hydroxychloroquine. On the other hand, we recommend 
conducting studies based on medical records analyzes, with 
the purpose of knowing specifically the proportion of each 
heart disease in patients affected by COVID-19.
Acknowledging such factors may help to better defining 
the risks of death among these COVID-19 patients, 
enabling a more targeted and specific approach to avoid 
probable deaths. In a scenario without effective antivirals 
or vaccines available, governments should apply continuous 
countermeasures for different pandemic situations to reduce 
mortality, especially in States with high percentages of ICU 
hospitalization and deaths.
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